← Back to Clinical Trials
Recruiting NCT07751172

NCT07751172 Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07751172
Status Recruiting
Phase —
Sponsor CooperVision International Limited (CVIL)
Condition Myopia
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2026-08-14
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 7 Years
Max Age 35 Years
Study Type INTERVENTIONAL
All Conditions
Interventions
Lens A (paflufocon D)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2026-08-14 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To evaluate the clinical performance and user-reported experience of Paragon CRT contact lenses with a 5mm Optic Zone Diameter (OZD)

Eligibility Criteria

Inclusion Criteria: A person is eligible for inclusion in the study if they: 1. Are 6- 35 years of age 2. If under 18 years old they are accompanied by a parent or legal guardian who is able to read, understand and sign the parental information and permission document 3. Have had a self-reported visual exam in the last two years 4. Are able to read (or be read to), understand and sign the assent document if under 18 years old or are able to read, understand and sign the consent document if aged 18 or older 5. Are willing to comply with the wear schedule (approximately 8 hours per night for every night, while sleeping) 6. Are willing to comply with the visit schedule 7. Have a refractive spherical component of their prescription between -0.50 and up to -6.00 diopters (inclusive) AND a refractive cylinder of no more than -1.75 diopters 8. Have a refractive spherical component ≥ cylinder component 9. Have a minimum visual acuity of +0.20 logMAR with each eye, when refracted at the Screening visit 10. Have clear corneas and no active ocular disease. 11. Have no medication, medical condition, or ocular conditions that contraindicate contact lens wear OR are expected to affect lens comfort or vision across the 1-month study duration, in the opinion of the investigator 12. Can be shown to have stable keratometry for at least the previous 1 month, if they have previously worn orthokeratology lenses. Exclusion Criteria: 1. Present at screening visit with the presence of ocular or systemic disease or report the use medications which might interfere with orthokeratology contact lens wear, such as keratoconus, diabetes mellitus, steroid eye drops 2. Have a post-treatment predicted flat K value ≤38.00D (e.g. Patient baseline flat keratometry value = 40.00, patient has 2.00D of myopic refractive error. 40.00-2.00= 38.00D) 3. Have a known sensitivity to the diagnostic sodium fluorescein to be used in the study 4. Are pregnant, planning a pregnancy or lactating 5. Have amblyopia 6. Have presbyopia or has dependence on spectacles for near work over the contact lenses 7. Present at screening visit with the presence of clinically significant (grade ≥3; ISO scale) anterior segment abnormalities. 8. Present at screening visit with slit lamp findings that would contraindicate orthokeratology contact lens wear such as: 1\. Pathological dry eye or associated findings 2. Pterygium, pinguecula, or corneal scars within the visual axis 3. Neovascularization \> 0.75 mm from of the limbus 4. Giant papillary conjunctivitis (GPC) worse than grade 1 5. Anterior uveitis or iritis (past or present) 6. Seborrheic eczema, Seborrheic conjunctivitis 7. History of corneal ulcers or fungal infections 8. Poor personal hygiene 9. Aphakia

Contact & Investigator

Central Contact

Kelly Voltz

✉ KVoltz@coopervision.com

📞 +19256604364

Frequently Asked Questions

Who can join the NCT07751172 clinical trial?

This trial is open to participants of all sexes, aged 7 Years or older, up to 35 Years, studying Myopia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07751172 currently recruiting?

Yes, NCT07751172 is actively recruiting participants. Contact the research team at KVoltz@coopervision.com for enrollment information.

Where is the NCT07751172 trial being conducted?

This trial is being conducted at Pleasanton, United States, Bellaire, United States, Madrid, Spain.

Who is sponsoring the NCT07751172 clinical trial?

NCT07751172 is sponsored by CooperVision International Limited (CVIL). The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology